Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115


Molecular profiling reveals frequent gain of MYCN and anaplasia-specific loss of 4q and 14q in Wilms tumor.

Williams RD, Al-Saadi R, Natrajan R, Mackay A, Chagtai T, Little S, Hing SN, Fenwick K, Ashworth A, Grundy P, Anderson JR, Dome JS, Perlman EJ, Jones C, Pritchard-Jones K.

Genes Chromosomes Cancer. 2011 Dec;50(12):982-95. doi: 10.1002/gcc.20907. Epub 2011 Aug 31.


Array comparative genomic hybridization reveals unbalanced gain of the MYCN region in Wilms tumors.

Schaub R, Burger A, Bausch D, Niggli FK, Schäfer BW, Betts DR.

Cancer Genet Cytogenet. 2007 Jan 1;172(1):61-5.


Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.

Williams RD, Al-Saadi R, Chagtai T, Popov S, Messahel B, Sebire N, Gessler M, Wegert J, Graf N, Leuschner I, Hubank M, Jones C, Vujanic G, Pritchard-Jones K; Children's Cancer and Leukaemia Group; SIOP Wilms' Tumour Biology Group.

Clin Cancer Res. 2010 Apr 1;16(7):2036-45. doi: 10.1158/1078-0432.CCR-09-2890. Epub 2010 Mar 23.


Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour.

Natrajan R, Little SE, Sodha N, Reis-Filho JS, Mackay A, Fenwick K, Ashworth A, Perlman EJ, Dome JS, Grundy PE, Pritchard-Jones K, Jones C.

J Pathol. 2007 Jan;211(1):52-9.


Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse.

Natrajan R, Williams RD, Hing SN, Mackay A, Reis-Filho JS, Fenwick K, Iravani M, Valgeirsson H, Grigoriadis A, Langford CF, Dovey O, Gregory SG, Weber BL, Ashworth A, Grundy PE, Pritchard-Jones K, Jones C.

J Pathol. 2006 Sep;210(1):49-58.


TP53 mutational status is a potential marker for risk stratification in Wilms tumour with diffuse anaplasia.

Maschietto M, Williams RD, Chagtai T, Popov SD, Sebire NJ, Vujanic G, Perlman E, Anderson JR, Grundy P, Dome JS, Pritchard-Jones K.

PLoS One. 2014 Oct 14;9(10):e109924. doi: 10.1371/journal.pone.0109924. eCollection 2014.


Chromosome analyses of 16 cases of Wilms tumor: different pattern in unfavorable histology.

Peres EM, Savasan S, Cushing B, Abella S, Mohamed AN.

Cancer Genet Cytogenet. 2004 Jan 1;148(1):66-70.


Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas.

Barrow J, Adamowicz-Brice M, Cartmill M, MacArthur D, Lowe J, Robson K, Brundler MA, Walker DA, Coyle B, Grundy R.

Neuro Oncol. 2011 Feb;13(2):212-22. doi: 10.1093/neuonc/noq158. Epub 2010 Dec 7.


Deletions of 16q in Wilms tumors localize to blastemal-anaplastic cells and are associated with reduced expression of the IRXB renal tubulogenesis gene cluster.

Mengelbier LH, Karlsson J, Lindgren D, Øra I, Isaksson M, Frigyesi I, Frigyesi A, Bras J, Sandstedt B, Gisselsson D.

Am J Pathol. 2010 Nov;177(5):2609-21. doi: 10.2353/ajpath.2010.100130. Epub 2010 Sep 16.


Screening for submicroscopic chromosomal rearrangements in Wilms tumor using whole-genome microarrays.

Rassekh SR, Chan S, Harvard C, Dix D, Qiao Y, Rajcan-Separovic E.

Cancer Genet Cytogenet. 2008 Apr 15;182(2):84-94. doi: 10.1016/j.cancergencyto.2007.12.015.


Multiple mechanisms of MYCN dysregulation in Wilms tumour.

Williams RD, Chagtai T, Alcaide-German M, Apps J, Wegert J, Popov S, Vujanic G, van Tinteren H, van den Heuvel-Eibrink MM, Kool M, de Kraker J, Gisselsson D, Graf N, Gessler M, Pritchard-Jones K.

Oncotarget. 2015 Mar 30;6(9):7232-43.


Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.

Yuan E, Li CM, Yamashiro DJ, Kandel J, Thaker H, Murty VV, Tycko B.

Mol Cancer Res. 2005 Sep;3(9):493-502.


Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis.

Wittmann S, Zirn B, Alkassar M, Ambros P, Graf N, Gessler M.

Genes Chromosomes Cancer. 2007 Feb;46(2):163-70.


Analysis of wilms tumors using SNP mapping array-based comparative genomic hybridization.

Hawthorn L, Cowell JK.

PLoS One. 2011 Apr 22;6(4):e18941. doi: 10.1371/journal.pone.0018941.


Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors.

Natrajan R, Little SE, Reis-Filho JS, Hing L, Messahel B, Grundy PE, Dome JS, Schneider T, Vujanic GM, Pritchard-Jones K, Jones C.

Clin Cancer Res. 2006 Dec 15;12(24):7284-93.


Complex patterns of chromosome 9 alterations including the p16INK4a locus in Wilms tumours.

Natrajan R, Warren W, Messahel B, Reis-Filho JS, Brundler MA, Dome JS, Grundy PE, Vujanic G, Pritchard-Jones K, Jones C.

J Clin Pathol. 2008 Jan;61(1):95-102. Epub 2007 Mar 16.


Accumulation of genomic aberrations during clinical progression of medulloblastoma.

Korshunov A, Benner A, Remke M, Lichter P, von Deimling A, Pfister S.

Acta Neuropathol. 2008 Oct;116(4):383-90. doi: 10.1007/s00401-008-0422-y. Epub 2008 Aug 15.


Cytogenetic abnormalities and clinical outcome in Wilms tumor: a study by the U.K. cancer cytogenetics group and the U.K. Children's Cancer Study Group.

Bown N, Cotterill SJ, Roberts P, Griffiths M, Larkins S, Hibbert S, Middleton H, Kelsey A, Tritton D, Mitchell C.

Med Pediatr Oncol. 2002 Jan;38(1):11-21.


Gain of 1q is associated with adverse outcome in favorable histology Wilms' tumors.

Hing S, Lu YJ, Summersgill B, King-Underwood L, Nicholson J, Grundy P, Grundy R, Gessler M, Shipley J, Pritchard-Jones K.

Am J Pathol. 2001 Feb;158(2):393-8.


Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.

Pfister S, Remke M, Benner A, Mendrzyk F, Toedt G, Felsberg J, Wittmann A, Devens F, Gerber NU, Joos S, Kulozik A, Reifenberger G, Rutkowski S, Wiestler OD, Radlwimmer B, Scheurlen W, Lichter P, Korshunov A.

J Clin Oncol. 2009 Apr 1;27(10):1627-36. doi: 10.1200/JCO.2008.17.9432. Epub 2009 Mar 2.

Items per page

Supplemental Content

Support Center